Attention deficit hyperactivity disorder (ADHD) - methylphenidate (replaced by TA98)

Methylphenidate, atomoxetine and dexamfetamine for the treatment of attention deficit hyperactivity disorder in children and adolescents (including a review of TA13)

Summary

This guidance has been replaced by Attention deficit hyperactivity disorder (ADHD) - methylphenidate, atomoxetine and dexamfetamine (review)

Guidance documents

• No documents found

Implementing this guidance

• No documents found

• How this guidance was produced
• Background information

• This guidance is currently being reviewed